Treace Medical reports Q2 EPS (28c), consensus (29c)

Reports Q2 revenue $47.39M, consensus $47.08M. “The second quarter was highlighted by solid progress in further addressing the needs of surgeons and patients with our expanded portfolio of best-in-class 3D bunion solutions as we delivered strong financial results and made meaningful progress on our strategic initiatives,” said John Treace, CEO, Founder and Chairman of Treace. “We are extremely pleased with the surgeon enthusiasm and patient outcomes experienced during the limited market releases of our Nanoplasty, Percuplasty, and SpeedMTP systems. We believe the demand for these new technologies, combined with our flagship Lapiplasty(R) and Adductoplasty systems, will establish Treace as the preeminent surgical bunion technology provider. We are excited to bring this comprehensive suite of bunion technologies to market and drive the next phase of growth for the Company.”